Summers Value Partners released its Q2 2025 investor letter, with the Summers Value Fund LP returning -1.8% net in Q2, down 12.8% YTD. Journey Medical Corporation (NASDAQ: DERM) was highlighted, with a one-month return of -1.35% and a stock value increase of 41.47% over 52 weeks, closing at $7.30 on Sept 19, 2025.

The Summers Value Fund expressed confidence in Journey Medical Corporation (NASDAQ: DERM), a dermatology-focused pharmaceutical company generating $55 million in revenue in 2024. Despite not being among the 30 most popular stocks among hedge funds, the company’s revenue for Q2 2025 was $15 million, showing potential for investment.

An article covered the surge of healthcare stocks in 2025, including Journey Medical Corporation (NASDAQ: DERM). For more investor letters from hedge funds and leading investors, visit the hedge fund investor letters Q2 2025 page. Check out “The Best and Worst Dow Stocks for the Next 12 Months” and “10 Unstoppable Stocks That Could Double Your Money.”

Read more at Yahoo Finance: Summers Value Partners’ Update on Journey Medical (DERM)